Australia markets closed

ZY Jan 2023 20.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
At close: 12:01PM EDT
Full screen
Previous close0.2000
Open0.2000
Bid0.0000
Ask4.8000
Strike20.00
Expiry date2023-01-20
Day's range0.2000 - 0.2000
Contract rangeN/A
Volume3
Open interest2.96k
  • Motley Fool

    Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future

    Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.

  • PR Newswire

    Ginkgo to Acquire Zymergen

    Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization. Under the terms of the agreement, which have been unanimously approved by the boards of directors of both companies, Zymergen stockholders will receive a

  • GlobeNewswire

    Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

    Octant doubles its initial investment in Zymergen’s Automation Technology to significantly increase the scale and throughput of its drug discovery platformEMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficie